Lynestrenol: Difference between revisions

	WikiDoc Resources for Lynestrenol
Articles
Most recent articles on Lynestrenol Most cited articles on Lynestrenol Review articles on Lynestrenol Articles on Lynestrenol in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Lynestrenol Images of Lynestrenol Photos of Lynestrenol Podcasts & MP3s on Lynestrenol Videos on Lynestrenol
Evidence Based Medicine
Cochrane Collaboration on Lynestrenol Bandolier on Lynestrenol TRIP on Lynestrenol
Clinical Trials
Ongoing Trials on Lynestrenol at Clinical Trials.gov Trial results on Lynestrenol Clinical Trials on Lynestrenol at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Lynestrenol NICE Guidance on Lynestrenol NHS PRODIGY Guidance FDA on Lynestrenol CDC on Lynestrenol
Books
Books on Lynestrenol
News
Lynestrenol in the news Be alerted to news on Lynestrenol News trends on Lynestrenol
Commentary
Blogs on Lynestrenol
Definitions
Definitions of Lynestrenol
Patient Resources / Community
Patient resources on Lynestrenol Discussion groups on Lynestrenol Patient Handouts on Lynestrenol Directions to Hospitals Treating Lynestrenol Risk calculators and risk factors for Lynestrenol
Healthcare Provider Resources
Symptoms of Lynestrenol Causes & Risk Factors for Lynestrenol Diagnostic studies for Lynestrenol Treatment of Lynestrenol
Continuing Medical Education (CME)
CME Programs on Lynestrenol
International
Lynestrenol en Espanol Lynestrenol en Francais
Business
Lynestrenol in the Marketplace Patents on Lynestrenol
Experimental / Informatics
List of terms related to Lynestrenol

Lynestrenol
Clinical data
AHFS/Drugs.com	International Drug Names
ATC code	G03AC02 (WHO) G03DC03 (WHO);; G03AA03 (WHO) G03AB02 (WHO) G03FA07 (WHO) G03FB02 (WHO) (combinations with estrogens);
Identifiers
	IUPAC name (8R,9R,10R,13S,14S,17S)-17-ethynyl-13-methyl-; 2,3,6,7,8,9,10,11,12,14,15,16-dodecahydro-; 1H-cyclopenta[a]phenanthren-17-ol;
CAS Number	52-76-6 ;
PubChem CID	5857;
ChemSpider	5648 ;
UNII	N2Z8ALG4U5;
KEGG	D01580 ;
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C20H28O
Molar mass	284.436 g/mol
3D model (JSmol)	Interactive image;
	SMILES C#C[C@]2(O)CC[C@H]1[C@H]4[C@H](CC[C@@]12C)[C@@H]3\C(=C/CCC3)CC4;
	InChI InChI=1S/C20H28O/c1-3-20(21)13-11-18-17-9-8-14-6-4-5-7-15(14)16(17)10-12-19(18,20)2/h1,6,15-18,21H,4-5,7-13H2,2H3/t15-,16+,17+,18-,19-,20-/m0/s1 ; Key:YNVGQYHLRCDXFQ-XGXHKTLJSA-N ;
(verify)

VisualWikitext

Revision as of 16:02, 10 April 2015

Template:Unreferenced stub

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Lynestrenol is a progestogen hormone. It is a synthetic orally-available progestagen associated with numerous effects of the natural progesterone hormone. Lynestrenol has a strong progestational effect on the uterine endometrium (transforming proliferative endometrium into secretory one), inhibits secretion of gonadotropin, suppresses maturation of follicles in the ovaries and ovulation, reduces menstrual bleeding. This synthetic gestagen is associated with minimal estrogenic, androgenic and anabolic effects. Lynestrenol is used in treatment of hormonal disorders and diseases caused by insufficient secretion of the natural progesterone, except in case of risky pregnancies and prevention of miscarriage, since it is not efficient enough in this indication.

Pharmacology

After oral administration lynestrenol is quickly resorbed and converted into pharmacologically active norethisterone, through which it demonstrates the main biological effects. The peak blood are reached within 2–4 hours after oral administration, 97% of the administered dose being bound to plasma proteins. Lynestrenol and its metabolites are predominantly excreted in the urine, less through feces, active metabolite norethisterone elimination halftime being 16-17 h.

References

Template:Progestogens

@@ Line 1: / Line 1: @@
+{{Unreferenced stub|auto=yes|date=December 2009}}
+{{Drugbox
+| verifiedrevid = 447623820
+| IUPAC_name = (8''R'',9''R'',10''R'',13''S'',14''S'',17''S'')-17-ethynyl-13-methyl-<br>2,3,6,7,8,9,10,11,12,14,15,16-dodecahydro-<br>1''H''-cyclopenta[a]phenanthren-17-ol
+| image = Lynestrenol.png
+<!--Clinical data-->
+| tradename =
+| Drugs.com = {{drugs.com|international|lynestrenol}}
+| pregnancy_category =
+| legal_status =
+| routes_of_administration =
+<!--Pharmacokinetic data-->
+| bioavailability =
+| metabolism =
+| excretion =
-{{Drugbox|
+<!--Identifiers-->
-|IUPAC_name = (8''R'',9''R'',10''R'',13''S'',14''S'',17''S'')-17-ethynyl-13-methyl-<br>2,3,6,7,8,9,10,11,12,14,15,16-dodecahydro-<br>1''H''-cyclopenta[a]phenanthren-17-ol
+| CAS_number_Ref = {{cascite|correct|??}}
-| image=Lynestrenol.svg
+| CAS_number = 52-76-6
-| CAS_number=52-76-6
+| ATC_prefix = G03
-| ATC_prefix=G03
+| ATC_suffix = AC02
-| ATC_suffix=AC02
+| ATC_supplemental = {{ATC|G03|DC03}};<br />{{ATC|G03|AA03}} {{ATC|G03|AB02}} {{ATC|G03|FA07}} {{ATC|G03|FB02}} (combinations with [[estrogen]]s)
-| ATC_supplemental=
+| PubChem = 5857
-| PubChem=5857
+| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
-| DrugBank=
+| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
-| C = 20 | H = 28 | O = 1
+| ChemSpiderID = 5648
+| UNII_Ref = {{fdacite|correct|FDA}}
+| UNII = N2Z8ALG4U5
+| KEGG_Ref = {{keggcite|correct|kegg}}
+| KEGG = D01580
+<!--Chemical data-->
+| C=20 | H=28 | O=1
 | molecular_weight = 284.436 g/mol
-| bioavailability=
+| smiles = C#C[C@]2(O)CC[C@H]1[C@H]4[C@H](CC[C@@]12C)[C@@H]3\C(=C/CCC3)CC4
-| metabolism =
+| InChI = 1/C20H28O/c1-3-20(21)13-11-18-17-9-8-14-6-4-5-7-15(14)16(17)10-12-19(18,20)2/h1,6,15-18,21H,4-5,7-13H2,2H3/t15-,16+,17+,18-,19-,20-/m0/s1
-| elimination_half-life=
+| InChIKey = YNVGQYHLRCDXFQ-XGXHKTLJBS
-| excretion =
+| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
-| pregnancy_category =
+| StdInChI = 1S/C20H28O/c1-3-20(21)13-11-18-17-9-8-14-6-4-5-7-15(14)16(17)10-12-19(18,20)2/h1,6,15-18,21H,4-5,7-13H2,2H3/t15-,16+,17+,18-,19-,20-/m0/s1
-| legal_status =
+| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
-| routes_of_administration=
+| StdInChIKey = YNVGQYHLRCDXFQ-XGXHKTLJSA-N
 }}
+__NOTOC__
 {{SI}}
-'''Lynestrenol''' is a [[progestagen]] hormone.
-[[Category:Progestagens]]
+{{CMG}}
-[[Category:Endocrinology]]
-{{Sex hormones}}
+==Overview==
-{{WikiDoc Help Menu}}
+'''Lynestrenol''' is a [[progestogen]] hormone. It is a synthetic orally-available progestagen associated with numerous effects of the natural progesterone hormone. Lynestrenol has a strong progestational effect on the uterine endometrium (transforming proliferative endometrium into secretory one), inhibits secretion of gonadotropin, suppresses maturation of follicles in the ovaries and ovulation, reduces menstrual bleeding.
-{{WikiDoc Sources}}
+This synthetic gestagen is associated with minimal estrogenic, androgenic and anabolic effects.
+Lynestrenol is used in treatment of hormonal disorders and diseases caused by insufficient secretion of the natural progesterone, except in case of risky pregnancies and prevention of miscarriage, since it is not efficient enough in this indication.
+==Pharmacology==
+After oral administration lynestrenol is quickly resorbed and converted into pharmacologically active [[norethisterone]], through which it demonstrates the main biological effects. The peak blood are reached within 2–4 hours after oral administration, 97% of the administered dose being bound to plasma proteins.
+Lynestrenol and its metabolites are predominantly excreted in the urine, less through feces, active metabolite norethisterone elimination halftime being 16-17 h.
+==See also==
+* [[Progestin]]
+* [[Progestogen]]
+* [[Progesterone]]
+==References==
+{{Reflist|2}}
+{{Progestogens}}
+{{Progestogenics}}
+[[Category:Progestogens]]
+[[Category:Drug]]

Lynestrenol: Difference between revisions

Revision as of 16:02, 10 April 2015

Overview

Pharmacology

See also

References

Navigation menu